Deutsch
English
Project manager: Prof. Dr.-Ing. G. Ziegmann
Funding period: 01/2017 - 06/2019
Funding agency: BMWi
Responsible: S. Sdrenka
Various methods are already available today for the separation of cells from whole blood samples, but these have limitations on the respective separation result. In the Zellclean project, IBA GmbH (www.iba-lifesciences.com/home.html) from Göttingen and the PuK at Clausthal University of Technology are working together on a new process to obtain cells of high purity, quality and yield. Using the TACS® ("traceless affinity cell selection") technology developed by IBA for reversible immunochromatography of cells in combination with the FABian® medical analysis device, the cells are to be separated specifically and in high quality from the remaining components using a separation matrix. Based on micro-injection molding technology, the core of the joint development is the separation unit with microstructured membranes as a multifunctional consumable through which the cell suspension is automatically flushed via the FABian®.
